AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abcellera Biologics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.298 Good afternoon and welcome to Abcelera's full year 2025 business update 00:00:05.298 -- 00:00:10.384 conference call. My name is Chelsea and I will facilitate the audio portion of today's 00:00:10.384 -- 00:00:13.025 interactive broadcast. 00:00:13.148 -- 00:00:17.253 After today's prepared remarks, we will host a question and answer session. 00:00:17.253 -- 00:00:22.300 If you would like to ask a question, please press star one on your 00:00:22.300 -- 00:00:24.302 telephone keypad. 00:00:24.302 -- 00:00:29.126 To withdraw your question, press star one again. 00:00:29.427 -- 00:00:34.952 At this time, I would like to turn the call over to Trin Stimart, Abcelera's 00:00:34.952 -- 00:00:39.954 Chief Legal and Compliance Officer. You may proceed. 00:00:40.517 -- 00:00:45.161 Thank you. Hello, everyone, and thank you for joining us today for Abcelera's full year 00:00:45.161 -- 00:00:50.505 2025 earnings call. I'm Trin Stimart, Abcelera's Chief Legal and Compliance 00:00:50.505 -- 00:00:55.810 Officer. Dr. Carl Hansen, Abcelera's President and CEO, and Andrew Booth, 00:00:55.810 -- 00:00:59.532 Abcelera's Chief Financial Officer, will be speaking on today's call. 00:00:59.532 -- 00:01:04.038 Also, Sarah Noonberg, our Chief Medical Officer, is on the call with us. 00:01:04.038 -- 00:01:08.083 During this call, we may make projections and forward-looking statements based on our 00:01:08.083 -- 00:01:12.548 current expectations and in accordance with the safe harbor provisions of the Private 00:01:12.548 -- 00:01:16.013 Securities Litigation Reform Act of 1995. 00:01:16.013 -- 00:01:20.678 Our actual results could differ materially due to factors as outlined in our latest Form 00:01:20.678 -- 00:01:26.600 10-K and subsequent Forms 10-Q an...